PEA 600-1200mg for Shift-Worker Neuropathy

Marcus is 41, hospital security supervisor at a level-one trauma center, overnight shift. 05:42, three hours into a day overtime he picked up because the holiday rotation was short-staffed. He is leaning against the wall outside the cardiac floor.

The burning in his feet has been waking him up at noon for nine months. Six months on gabapentin. His PCP keeps escalating dose. The pain backs off; the fog never lifts.

He cannot remember why he walked into the break room.

He is on the same hospital tile I used to walk at 308 pounds, except mine were security rounds and the foot pain was a load problem. His feet are not a load problem. His feet are a molecule problem.

There is a fatty acid sitting in the medical literature for thirty years that his pain clinic should have handed him instead of the brain-fog drug.

TL;DR - Paladini 2016 (Pain Physician, 12 RCTs, n=1,484) put PEA's number-needed-to-treat for 50% pain reduction at 1.5. - Gabapentin's NNT on the same endpoint sits at 6 to 8 (Cochrane 2017), with cognitive fog as the price tag. - Ultramicronized PEA hits 1.75x the plasma of standard PEA at the same oral dose (Petrosino & Di Marzo, BJP 2017). Particle size is the whole game. - Protocol: 600mg ultramicronized PEA twice daily with fat. Loading dose 1200mg twice daily for 30-60 days for severe presentations. - Most responders cross the 50% pain threshold between day 14 and day 21, with continued improvement through day 60.

What PEA actually is

Palmitoylethanolamide is a fatty acid amide your body builds on demand at sites of tissue stress. Egg yolk has it. Peanut meal has it.

It was first isolated in 1957, characterized as an anti-inflammatory in the 1990s, then ignored by the U.S. supplement industry for thirty years for one reason. It is not patentable and does not get you high.

Italy figured it out in 2008 and has been prescribing it as a medical food (Normast, PeaPure, Glialia) ever since. Three mechanisms run in parallel, and gabapentin misses every one of them.

PEA is a high-affinity agonist at PPAR-alpha, a nuclear receptor that turns down the NF-kB cascade driving chronic neuroinflammation. Same receptor family fenofibrate hits, but PEA stays in the inflammation lane.

It also stabilizes mast cells. When a peripheral nerve gets mechanically irritated for hours at a stretch, surrounding mast cells dump histamine, tryptase, TNF-alpha, and nerve growth factor. That cascade shows up loud in CIDP, fibromyalgia, post-viral pain, and the pressure-and-vibration neuropathy that builds in anyone who stands on hard floors for a decade.

Third, PEA blocks the FAAH enzyme that degrades anandamide, lengthening your endogenous cannabinoid signal at the injury site. The entourage effect without the high, the tolerance, or the dependency.

Gabapentin, by contrast, jams the alpha-2-delta subunit of voltage-gated calcium channels and blunts the entire central nervous system. The on-label profile: somnolence in 20%, dizziness in 17%, peripheral edema in 8%, weight gain, ataxia, and the cognitive slowing patients describe in every survey.

Marcus is not imagining the fog.

The numbers that should have changed practice

Paladini and colleagues published a meta-analysis in Pain Physician in 2016. Twelve randomized controlled trials, 1,484 patients, across diabetic neuropathy, sciatica, post-herpetic neuralgia, carpal tunnel, and chemo-induced peripheral neuropathy.

The pooled NNT for 50% pain reduction came in at 1.5. That means you treat between one and two patients to get one responder at the clinically meaningful threshold.

Roughly four times better than gabapentin, with an adverse-event profile statistically indistinguishable from placebo.

Cocito et al, CNS Neuroscience and Therapeutics 2014, ran a 30-day trial on sciatic nerve pain. PEA arm dropped VAS 50.1%. Placebo dropped 34.9%. Pain studies have legendary placebo effects. PEA cleared it cleanly, with separation visible by day 10.

This is the kind of effect-size gap HERMES, our research worker, surfaces when it scrapes the 12,000+ fitness and pain papers indexed every week. The moment a 2026 trial drops, your protocol updates. You do not wait for a guideline committee to catch up six years later.

Why this hits shift workers and CIDP populations specifically

Stand at handoff at 07:00 in any urban hospital and you see the same neurological pattern on repeat. Night-shift nurses, six to eighteen months in, developing burning feet, stocking-distribution numbness, and the specific medial-plantar gait change that says the nerve is irritated.

Twelve hours on concrete subfloor under fluorescent light, with circadian disruption suppressing the cortisol rhythm that normally controls inflammatory tone. It is mechanistically distinct from diabetic neuropathy and presents identically. Marcus is in the same physiology — twelve-hour overnight shifts on hospital tile, eighteen months in. His pain clinic treats it like diabetic neuropathy because that is the only ladder the clinic knows.

CIDP is a separate population with overlapping management. Chronic inflammatory demyelinating polyneuropathy is run with IVIG, subcutaneous immunoglobulin, or corticosteroids. Pain gets the gabapentin-pregabalin-duloxetine ladder as a secondary patch.

A 2014 Italian observational cohort in carpal tunnel patients and a 2017 paper in the Journal of Pain Research on diabetic peripheral neuropathy both flagged PEA as a useful adjunct for patients who cannot afford the cognitive tax of CNS depressants.

This is exactly the pattern Chiron, the LIM AI head coach, flags in the daily program review. If your check-in voice note shows up slow, your sleep score has been under 80 for a week, and your activity log says twelve-hour standing days, the system is already proposing a peripheral-neuro support stack before you ask for it.

Ultramicronized versus standard: this is the whole game

PEA is fat soluble and absorbs poorly in its native crystalline form. Particle size is the rate-limiter.

Standard PEA: 100 to 700 micrometers. Micronized: around 6 micrometers. Ultramicronized: 0.8 to 2 micrometers.

That is the form used in essentially every positive Italian RCT, including Cocito's. Petrosino and Di Marzo, British Journal of Pharmacology 2017, quantified it: ultramicronized hits 1.75x the plasma concentration at equivalent oral doses, with a flatter absorption curve and measurably better penetration into nervous tissue.

Impellizzeri 2014 in the Journal of Neuroinflammation showed the same separation at the tissue level.

Buy bulk PEA powder off a U.S. aggregator at $18 for 250g and you are almost certainly getting standard particle size. You are eating two to three times the dose to get equivalent tissue exposure. Or, more often, you are eating placebo and writing the molecule off.

Look for "ultramicronized" or "um-PEA" on the label, plus a published particle size spec. If it is not on the label, the absorption is roughly half what the trial data describes.

This is the single most common reason a PEA protocol underperforms.

Where this fits in a shift-worker stack

Protocol that aligns with the published data: 600mg ultramicronized PEA twice daily for 30 days, with a fat-containing meal. For CIDP-adjacent or severe diabetic presentations, push to 1200mg twice daily for the loading phase, then drop to 600mg twice daily for maintenance.

Most responders feel meaningful relief between day 14 and 21, with continued improvement through day 60. This is not an analgesic you take for a flare. It is a signaling reset you take on a schedule.

For the night-shift worker already on gabapentin who wants out, the cleanest taper is to add ultramicronized PEA at 600mg twice daily for 60 days while holding gabapentin steady, then taper gabapentin by 25% every two weeks under physician supervision.

Pair it with the nerve-floor stack:

• Alpha-lipoic acid 600mg AM. Ziegler 2011 in *Diabetes Care* put symptomatic diabetic neuropathy NNT at roughly 4.
• Methylcobalamin 1mg sublingual, not cyanocobalamin. The cyano group has to be cleaved before the methyl donor is bioavailable.
• Methylfolate 400-800mcg for one-carbon metabolism.
• Magnesium glycinate 300-400mg at night for NMDA tone.
• D3 5000 IU with K2 MK-7 100mcg at the largest fat-containing meal, dosed to 25-OH serum above 50 ng/mL. Below 30 ng/mL independently worsens small-fiber neuropathy and is functionally universal in shift workers who never see daylight.

The whole stack lives on the LIM /recommended page so you are not paying retail at the airport supplement counter or playing roulette with Amazon counterfeits.

None of this is a fix for compressive neuropathy from a herniated disc. It is not a substitute for losing the mechanical load if the load is the variable. I lost 112 pounds before I had the standing to write this paragraph.

For the night-shift nurse three years into rotation who cannot change the schedule, or the CIDP patient whose pain breaks through immunoglobulin therapy, PEA gives the nervous system a chemical floor to stop misfiring without the cognitive tax that makes the standard drug feel like trading one disability for another.

What we do with this in LIM

Marcus does not need a gabapentin taper-and-replace protocol decoded by Reddit at 3 a.m. He needs the protocol, the particle-size warning, the ALA-B12-D3 floor under it, and someone watching his sleep score and voice-note for eight weeks to confirm the stack is actually pulling.

That is a six-tab spreadsheet for most coaches. In LIM it is one app.

The voice-note check-in catches the cortisol-tell in your tone before the scale or the sleep ring moves. The Apple Watch and HealthKit feed populates the daily program update worker, which rewrites your week the moment your standing minutes spike past your recovery capacity. Chiron flags the neuropathy pattern in its daily review and pushes the stack adjustment through to your dashboard.

The molecule has been sitting in the literature for three decades. The meta-analysis has been sitting there since 2016.

Not exotic. Not a peptide. A fatty acid your liver builds when you are stressed, sold over the counter, with an NNT that should embarrass the prescribing guidelines.

Sixty days at full ultramicronized dosing before you judge the response.

If you want the protocol built for your shift schedule, your sleep data, and your existing meds, that is what we do at Legacy In Motion.

---

The data behind this

• Paladini et al., *Pain Physician*, 2016 — meta-analysis (12 RCTs, n=1,484), PEA NNT = 1.5 for 50% pain reduction.
• Cochrane 2017 — gabapentin NNT 6 to 8 on the same endpoint.
• Petrosino & Di Marzo, *British Journal of Pharmacology*, 2017 — ultramicronized PEA achieves 1.75x plasma concentration vs. standard PEA.
• Cocito et al., *CNS Neuroscience and Therapeutics*, 2014 — 30-day sciatic nerve pain trial, VAS 50.1% vs. 34.9% placebo.
• Impellizzeri, *Journal of Neuroinflammation*, 2014 — tissue-level separation between ultramicronized and standard PEA.
• *Journal of Pain Research*, 2017 — PEA as adjunct in diabetic peripheral neuropathy.
• Ziegler, *Diabetes Care*, 2011 — alpha-lipoic acid in symptomatic diabetic neuropathy.